Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ:ELDN
ELDN Stock Chart & Stats
$3.10
-$0.17(-3.66%)
At close: 4:00 PM EST
$3.10
-$0.17(-3.66%)
Day’s Range― - ―
52-Week Range$1.35 - $4.60
Previous CloseN/A
Volume121.23K
Average Volume (3M)1.17M
Market Cap
$232.76M
Enterprise Value$151.09M
Total Cash (Recent Filing)$133.34M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding75,084,694
10 Day Avg. Volume1,846,980
30 Day Avg. Volume1,171,704
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$7.33Price Target Upside136.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyTegoprubart produced rapid and sustained improvements in kidney filtration and transplant organ function in clinical studies, suggesting potential to improve long-term graft survival.
Regulatory Engagement And External FundingPlanned engagement with the FDA on islet transplant data alongside committed funding for a second study supports a clearer regulatory development path and reduces execution uncertainty.
Safety And TolerabilityTegoprubart showed a favorable safety profile with fewer rejection episodes, lower incidence of new-onset diabetes, and fewer neurological symptoms versus standard immunosuppression, supporting a differentiated treatment profile.
Bears Say
Active Comparator PerformanceStronger-than-expected efficacy of the control drug in the trial raises the bar for tegoprubart to demonstrate clear superiority on the primary kidney endpoint, increasing clinical development risk.
Cash Runway And Financing RiskLimited cash runway given current cash burn creates uncertainty about the ability to advance larger pivotal trials without additional financing, which could dilute shareholders or delay development.
Small Trial Size And Statistical UncertaintySmall patient numbers in investigator-led and company studies limit confidence that observed benefits will hold in a larger population, heightening outcome uncertainty for pivotal trials.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals, Inc.’s price range in the past 12 months?
Eledon Pharmaceuticals, Inc. lowest stock price was $1.35 and its highest was $4.60 in the past 12 months.
What is Eledon Pharmaceuticals, Inc.’s market cap?
Eledon Pharmaceuticals, Inc.’s market cap is $232.76M.
When is Eledon Pharmaceuticals, Inc.’s upcoming earnings report date?
Eledon Pharmaceuticals, Inc.’s upcoming earnings report date is May 07, 2026 which is in 42 days.
How were Eledon Pharmaceuticals, Inc.’s earnings last quarter?
Eledon Pharmaceuticals, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.125 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.078.
Is Eledon Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Eledon Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Eledon Pharmaceuticals, Inc. pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
What is Eledon Pharmaceuticals, Inc.’s EPS estimate?
Eledon Pharmaceuticals, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Eledon Pharmaceuticals, Inc. have?
Eledon Pharmaceuticals, Inc. has 75,084,694 shares outstanding.
What happened to Eledon Pharmaceuticals, Inc.’s price movement after its last earnings report?
Eledon Pharmaceuticals, Inc. reported an EPS of -$0.125 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went up 1.053%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (136.45% Upside)
$7.33 (136.45% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.94%
12-Months-Change
Fundamentals
Return on Equity
-46.46%
Trailing 12-Months
Asset Growth
3.56%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$7.33
▲(136.45% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
0.03% Insiders
6.96% Mutual Funds
33.66% Other Institutional Investors
51.87% Public Companies and
Individual Investors